Skip to main content
Midas Edge

CHEMED CORP

For the period ended Dec 31, 2025. Filed Feb 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 27, 2026

CHE$544.49+1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

Item 15Exhibits and Financial Statement Schedule
Exhibits
3.1Certificate of Incorporation of Chemed Corporation.*
3.2Certificate of Amendment to Certificate of Incorporation, dated May 15, 2006.*
3.3By-Laws of Chemed Corporation, as amended December 9, 2022*
4.1Description of Securities.*
10.12006 Stock Incentive Plan, as amended August 11, 2006.*,**
10.22010 Stock Incentive Plan.*,**
10.32015 Stock Incentive Plan*,**
10.42018 Stock Incentive Plan*,**
10.52022 Stock Incentive Plan*,**
10.62025 Stock Incentive Plan*,**
10.7Consulting Agreement with Timothy S. O'Toole dated June 16, 2016.*,**
10.8Employment Agreement with Kevin J. McNamara dated May 3, 2008.*,**
10.9First Amendment to Employment Agreement with Kevin J. McNamara dated July 9, 2009.*,**
10.10Excess Benefits Plan, as restated and amended, effective June 1, 2001.*,**
10.11Amendment No. 1 to Excess Benefits Plan, effective July 1, 2001.*,**
10.12Amendment No. 2 to Excess Benefits Plan, effective November 7, 2003.*,**
10.13Non-Employee Directors’ Deferred Compensation Plan.*,**
10.14Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 1999.*,**
10.15First Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective September 6, 2000.*,**
10.16Second Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 2001.*,**
10.17Third Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective December 12, 2001.*,**
10.18Directors Emeriti Plan.*,**
10.19Chemed Corporation Change in Control Severance Plan, as amended August 3, 2018.**
10.20Chemed Corporation Senior Executive Severance Policy, as amended August 3, 2018**
10.21Roto-Rooter Deferred Compensation Plan No. 1, as amended January 1, 1998.*,**
10.22Roto-Rooter Deferred Compensation Plan No. 2.*,**
10.23Form of Performance-Based Restricted Stock Units Award*,**
10.24Form of Stock Option Grant, pre-2013.*,**
10.25Form of Stock Option Grant, 2013.*,**
10.26Form of Stock Option Grant, 2015. ,*
10.27Form of Stock Option Grant, 2018. ,*
10.28Form of Stock Option Grant, 2022. ,*
10.29Form of Stock Option Grant, 2025. ,*
10.30Settlement Agreement, effective October 30, 2017 by and among the United States of America, acting through the United States Department of Justice and on behalf of the Office of the Inspector General of the Department of Health and Human Services, VITAS Hospice Services, L.L.C., VITAS Healthcare Corporation, VITAS Healthcare Corporation of California, VITAS Healthcare Corporation of Illinois, VITAS Healthcare Corporation of Florida, Vitas Healthcare Corporation of Ohio, VITAS Healthcare Corporation of Atlantic, VITAS Healthcare of Texas, L.P., VITAS Healthcare Corporation Midwest, VITAS Healthcare Corporation of Georgia, Chemed Corporation, and the various Relators named therein.*
10.31Corporate Integrity Agreement, effective October 30, 2017 between the Office of Inspector General of the Department of Health and Human Services and VITAS Hospice Services, L.L.C., VITAS Healthcare Corporation, VITAS Healthcare Corporation of California, VITAS Healthcare Corporation of Illinois, VITAS Healthcare Corporation of Florida, VITAS Healthcare Corporation of Ohio, VITAS Healthcare Corporation of Atlantic, VITAS Healthcare of Texas, L.P., VITAS Healthcare Corporation Midwest and VITAS Healthcare Corporation of Georgia.*
10.32Fifth Amended and Restated Credit Agreement by and among Chemed Corporation, JP Morgan Chase Bank NA, and other lenders as of June 28, 2022*
10.33David P. Williams Agreement
10.34Nicholas M. Westfall Transition and Separation Agreement, Filed as Exhibit 10.1, attached to the Form 10-Q filed July 31, 2025
14Policies on Business Ethics of Chemed Corporation
19Insider Trading Policy of Chemed Corporation
21Subsidiaries of Chemed Corporation.
23Consent of Independent Registered Public Accounting Firm.
24Powers of Attorney.
31.1Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
31.2Certification by Michael D. Witzeman pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
32.1Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification by Michael D. Witzeman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97Compensation Recovery Policy
101.INSXBRL Instance Document*
101.SCHXBRL Extension Schema*
101.CALXBRL Taxonomy Extension Calculation Linkbase*
101.DEFXBRL Taxonomy Extension Definition Linkbase*
101.LABXBRL Taxonomy Extension Label Linkbase*
101.PREXBRL Taxonomy Extension Presentation Linkbase*
*This exhibit is being filed by means of incorporation by reference (see Index to Exhibits on page E-1). Each other exhibit is being filed with this Annual Report on Form 10-K.
**Management contract or compensatory plan or arrangement.
Financial Statement Schedule
See Index to Financial Statements and Financial Statement Schedule on page S-1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.